WEST TISBURY, Massachusetts

Radikal Therapeutics today announced that the Company has been joined by Dr. Rex Gallagher, who will assume the position of Director of Analytical Chemistry. Dr. Gallagher is an experienced bioanalytical mass spectroscopist. He has outstanding experience in natural products research and small molecule drug development in private industry, government, and academia. Dr. Gallagher has worked with cardiac glycosides and natural cardenolides as sodium pump modulators for five years, and anticancer taxanes for over five years. He has specialist knowledge and experience in separations technology and mass spectroscopy. In particular he has over 30 years hands-on experience operating numerous mass spectrometers and setting up analytical laboratories. He has effectively applied expertise in these areas to structure elucidation of a wide array of small molecules, including especially natural products, pharmaceuticals, impurities, contaminants, degradation products and metabolites. He has a number of years experience in in vitro and in vivo metabolism studies, including metabolite ID, CYP450 cross-species comparisons and metabolic pathway elucidation. Dr. Gallagher has managed patent portfolios and patent office actions and is an inventor on 12 patents and author of more than 50 peer-reviewed publications. He has a PhD in Chemistry from Massey University, New Zealand, and was a Fulbright Scholar and Visiting professor to the University of Pennsylvania in 1990.

About Radikal Therapeutics (RTX)

RTX is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, the Company is positioned to remain at the forefront of drug discovery. RTX’s team of chemists, biologists, immunologists, and drug development professionals has worked together for more than two decades and has built a reputation for leadership in basic science and drug development. The Company is developing best-in-class therapeutics in a range of clinical areas, including inflammation, ischemia-reperfusion injury, and auto-immunity. The product platforms include small and large molecule pharmaceuticals that therapeutically restore free radical equilibrium, redirect aberrant signaling pathways in inflammation, manipulate mitochondrial cell death pathways, modulate DNA repair, restore microcirculatory perfusion, and induce specific immunotolerance. Although varied in their structural targets and directed at diverse clinical needs, the Company’s technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents.

Via its sister firm Luria Scientific Industries (LSI), RTX makes available its deep and unique experience in pre-clinical and clinical development for the benefit of the biotech and pharmaceutical industry.


Andrew L. Salzman, M.D.



1-866-925-2871 x.709